TME Pharma Valuation

Is ALTME undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALTME when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ALTME's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALTME's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALTME?

Key metric: As ALTME is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ALTME. This is calculated by dividing ALTME's market cap by their current book value.
What is ALTME's PB Ratio?
PB Ratio	4.1x
Book	€1.57m
Market Cap	€6.36m

ALTME key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-0.7x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does ALTME's PB Ratio compare to its peers?

The above table shows the PB ratio for ALTME vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	1.1x
ALNOV Novacyt	0.5x	n/a	€40.6m
ALVIO Valerio Therapeutics Société anonyme	3x	n/a	€11.9m
PHXM PHAXIAM Therapeutics	0.6x	-3.5%	€15.9m
ALCOX Nicox	0.3x	15.3%	€15.1m
ALTME TME Pharma	4.1x	n/a	€6.4m

Price-To-Book vs Peers: ALTME is expensive based on its Price-To-Book Ratio (4.1x) compared to the peer average (1.1x).

Price to Book Ratio vs Industry

How does ALTME's PB Ratio compare vs other companies in the FR Biotechs Industry?

2 Companies	Price / Book	Estimated Growth	Market Cap
ALVET TheraVet	0.05x	n/a	US$297.34k
ALNEV Neovacs	0.0001x	n/a	US$1.94k

No more companies available in this PB range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: ALTME is expensive based on its Price-To-Book Ratio (4.1x) compared to the French Biotechs industry average (1.9x).

Price to Book Ratio vs Fair Ratio

What is ALTME's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALTME PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	4.1x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ALTME's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sanofi

€116.8b

A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.

SAN

€93.17

2.0%

7.9%

Theranexus Société Anonyme

€3.9m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

ALTHX

€0.50

-57.2%

Eurofins Scientific

€8.9b

Provides various analytical testing and laboratory services worldwide.

ERF

€46.96

3.3%

-12.0%